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Abstract
Background: The p53 tumor suppressor, which is altered in most cancers, is a sequence-specific transcription factor that is
able to modulate the expression of many target genes and influence a variety of cellular pathways. Inactivation of the p53
pathway in cancer frequently occurs through the expression of mutant p53 protein. In tumors that retain wild type p53, the
pathway can be altered by upstream modulators, particularly the p53 negative regulators MDM2 and MDM4.
Methodology/Principal Findings: Given the many factors that might influence p53 function, including expression levels,
mutations, cofactor proteins and small molecules, we expanded our previously described yeast-based system to provide the
opportunity for efficient investigation of their individual and combined impacts in a miniaturized format. The system
integrates i) variable expression of p53 proteins under the finely tunable GAL1,10 promoter, ii) single copy, chromosomally
located p53-responsive and control luminescence reporters, iii) enhanced chemical uptake using modified ABC-transporters,
iv) small-volume formats for treatment and dual-luciferase assays, and v) opportunities to co-express p53 with other
cofactor proteins. This robust system can distinguish different levels of expression of WT and mutant p53 as well as
interactions with MDM2 or 53BP1.
Conclusions/Significance: We found that the small molecules Nutlin and RITA could both relieve the MDM2-dependent
inhibition of WT p53 transactivation function, while only RITA could impact p53/53BP1 functional interactions. PRIMA-1 was
ineffective in modifying the transactivation capacity of WT p53 and missense p53 mutations. This dual-luciferase assay can,
therefore, provide a high-throughput assessment tool for investigating a matrix of factors that can influence the p53
network, including the effectiveness of newly developed small molecules, on WT and tumor-associated p53 mutants as well
as interacting proteins.
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Introduction
The sequence-specific transcription factor p53 is a key tumor
suppressor protein that can coordinate the expression of a large
number of target genes involved in different cellular responses to
stress conditions including cell cycle arrest, programmed cell death
and DNA repair [1,2]. More recently, a role of p53 in a diverse
spectrum of cellular pathways has been established, including
angiogenesis, autophagy, as well as carbon and lipid metabolism
[3,4,5]. p53 activity is finely tuned by a large number of signaling
pathways which respond to alterations in cellular homeostasis or
the microenvironment and result in the modulation of p53 protein
levels, the potential for protein:protein interactions and DNA
binding affinity/specificity. Modulation of the p53 network mainly
occurs via post-translational modifications of the p53 protein itself
[6]. The critical importance of p53 in tumor suppression in
humans is exemplified by the high frequency of human cancers
showing alterations in the p53 pathway, including p53 mutations
[7].
Many studies in a variety of cell lines and in vivo animal models
have provided striking evidence that the reconstitution of p53
activity can lead to tumor cell death as well as to the regression of
established tumors [8,9,10,11,12]. Over the past 15 years such
results have spurred a number of studies aimed at developing the
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Cmeans for restoring wild type p53 function in cells including viral
delivery of p53 cDNAs and the rational design of small molecules
or peptides that can stimulate p53 functions or reactivate tumor-
associated mutant p53 proteins [13,14,15]. In tumors that retain
wild type p53, the regulated pathway is frequently, if not always,
impaired by other genetic events that result in higher expression
and activity of the critical negative p53 regulator MDM2 or, to a
lesser extent MDM4 and other modulators of p53 protein
localization and activity [16,17,18,19]. The critical roles of
MDM2 and MDM4 as negative modulators of p53, which have
been elegantly established using knock-out models [20,21], as well
as the over-expression of these proteins in several cancer types
[17,22,23] raised expectations on the therapeutic potential of
restoring p53 functions by MDM2/4 in tumors. However, the
identification of chemicals that could disrupt protein:protein
interactions or protein:DNA interactions involving p53 has proven
challenging [24].
Small molecules that can inhibit the interaction between
MDM2 and p53 can result in increased p53 protein levels and
lead to p53-dependent growth suppression and apoptosis in
different cell-based as well as in vivo models [25,26,27]. For
example, Nutlin and the MI-43 compounds target the binding
pocket for p53 in the MDM2 protein. RITA, which was identified
in a cell-based screening assay, binds p53 and also inhibits the
p53:MDM2 interaction [25]. Structural studies have identified
similarities as well as shape differences between the p53-binding
pockets in MDM2 and MDM4 [28], supporting the selectivity of
Nutlin in p53:MDM2 interactions [29].
To investigate the impact of small molecules on p53
transactivation potential or on the functional interaction between
p53 and cofactors, we have developed a highly defined dual-
luciferase functional assay in the budding yeast Saccharomyces
cerevisiae. This greatly expands our previous system designed to
address functions of p53 mutants and target response elements by
varying the level of p53 [30,31]. The assay exploits the variable
expression of p53 proteins and utilizes the Firefly and Renilla
luminescent reporters integrated as single copies at different
chromosomal loci in haploid strains or at the same chromosomal
location in diploid strains, i.e., heteroalleles. While a common
minimal promoter controls low-level constitutive expression of
both reporters, p53-dependent expression of the Firefly reporter is
attained through a specific p53 response element (RE) placed
upstream of the minimal promoter [32,33].
The sensitivity and robustness of the assay system was
investigated with various protocols for induction of wild type and
mutant p53 protein as well as coincident measurement of the two
luciferases. This was followed by an examination of the ability of the
dual assay system to discern the functional interaction of wild type
and mutant p53 when co-expressed with MDM2 or 53BP1 and the
effects of RITA and Nutlin. Our results establish that the functional
interactionsaswellastheimpactofthesmallmoleculesweredistinct
anddependonthenature ofthep53mutants.Theresponsivenessto
these chemicals did not extend to PRIMA-1 which has been
reported to restore apoptotic activity of specific tumor-associated
p53 missense mutants in engineered cancer cells [34,35,36]. We
propose that our dual-luciferase yeast assay can be applied to the
study of small molecules in order to investigate their differential
impactonalargenumberoftumor-associated p53mutationsaswell
as partial inactivation of wild type p53 [37]. Furthermore, unlike
other p53 screening systems, our genetically well-defined, cell-based
assay can be applied to high-throughput screening (HTS) of
chemicals toward a matrix of factors that can influence the p53
network including p53 protein levels, p53 mutations, nature of the
p53 REs, and level of p53-interacting proteins.
Materials and Methods
Drugs, plasmids and media
RITA was purchased from Cayman Chemical (Cayman
Europe, Tallinn, Estonia), Nutlin from Alexis Biochemicals (Enzo
Life Sciences, Milan, Italy), and PRIMA-1 was obtained from
Inalco (Inalco, Milan, Italy). Stock solutions of the compounds
were prepared at the concentration of 10 mM; RITA and Nutlin
were prepared in DMSO while PRIMA-1 was dissolved in water.
Working dilutions were freshly prepared in yeast culture media
immediately before treatment.
pTSG-hp53 was used to express human wild type or mutant
p53 protein under the control of the GAL1 inducible promoter.
The plasmid is based on the centromeric pRS314 vector and
contains the TRP1 selection marker. Plasmids pRB254 and
pRB759 were used to express MDM2 and 53BP1, respectively.
These HIS3-marked plasmids were obtained from Rainer
Brachmann (Irvine University, CA, USA) and contain full-length
MDM2 or a 53BP1 fragment lacking the first 970 amino acids,
that are constitutively expressed under the PGK1 and ADH1
promoter, respectively. Given that our luciferase reporter strains
could not support HIS3-based plasmid selection due to a cryptic
mutation in the histidine biosynthesis pathway, to conduct
experiments with the co-expression of p53 and MDM2 or
53BP1 we constructed a diploid yeast reporter strain by mating
our strain (whose construction is described below) yLFM-PUMA,
RFM-M2, Dpdr5 [Mata his-, leu2, trp1, ura3, ade2::cyc1-LUC,
pdr5::cyc1-REN] with the BY4704 strain (Mata ade2::hisG; Dhis3-
200; leu2-D0; lys2-D0; met15-D0; trp1-D63, where ‘‘D0’’ indicates
complete removal of the ORF sequence). The resulting diploid is
heterozygous for Dpdr5. Plasmids were transformed into yeast cells
using the standard LiAc protocol. Transformants were picked and
purified on selective plates containing glucose as carbon source.
To conduct the luciferase assays while exploiting variable
induction of p53 proteins, yeast cells were cultured in liquid
media containing 2% raffinose (Sigma-Aldrich, Milan, Italy) as
carbon source or 2% raffinose supplemented with different
amount of galactose (Sigma-Aldrich) as inducer of the GAL1
promoter (as indicated in the Results section and Figure Legends)
following the protocol developed previously [31,32,33,38]. All
media components were obtained from BD-Bioscience (BD-
Biosciences Italy, Milan, Italy) or Sigma-Aldrich. 5-Fluoroorotic
Acid was purchased from Toronto Research Chemicals Inc.
(North York, Ontario, Canada). The integrative plasmid
pdr1DBD-repressor (sin3) was a generous gift of Dr. John Nitiss
(St. Jude Children’s Hospital, TN, USA) and was used to disrupt
the regulator of the ABC transporter system PDR1 gene by
replacing it with a fusion construct whereby the PDR1 DNA
binding domain is fused with the SIN3 transcriptional repression
domain [39].
Development of dual-luciferase yeast reporter strains
The Renilla luciferase open reading frame (ORF) was amplified
from the pRL-SV40 vector (Promega, Milan, Italy) and integrated
at the ADE2 locus using the delitto perfetto approach [40] starting
from the available y-FM-cyc1-ICORE- strain [32]. This strain
contains the targeting module, consisting of the I-SceI recognition
site and GAL1-I-SceI expression cassette, that provides for
generation of a single, site-specific double strand break by the
homing endonuclease I-SceI. The targeting module also contains a
URA3 and a KANMX4 marker, respectively, for counter-selection
on plates containing 5-fluoro-orotic acid and forward selection for
G418 resistance [41]. The ICORE was integrated by exploiting
homologous recombination downstream of the minimal CYC1
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developed yAFM strains [38]. ICORE replacement with the
Renilla ORF resulted in the yRFM (R = Renilla) strain which was
further modified by introducing the ICORE cassette upstream of
the minimal CYC1 promoter. The resulting yRFM-ICORE strain
was then used to develop desired p53 RE insertions upstream of
the CYC1 promoter by targeting the ICORE site with oligonucle-
otides containing the chosen RE sequences, as previously
described [38]. To develop dual-luciferase yeast reporter strains
two approaches were followed. To construct an isogenic diploid
reporter, the yRFM strain, in which Renilla is expressed at basal
levels, was transformed by pGAL-HO plasmid [42,43] and
cultured in galactose to induce expression of the HO endonuclease
in order to induce mating type switching. The yRFM, Mata
derivatives were identified by crosses with mating type testers,
purified and then used in a cross with the yLFM-PUMA p53
reporter strain. The resulting diploid strain is isogenic, but hetero-
allelic at the ADE2 locus, in that one chromosome contains the
Firefly luciferase, while the other contains Renilla. The diploid
version of the assay was used for the experiments investigating the
impact of MDM2 or 53BP1 on p53 transactivation potential.
A haploid dual-luciferase reporter strain was also developed
placing the CYC1-Renilla construct at the PDR5 locus. First, we
targeted the PDR5 gene that codes for a p-glycoprotein whose
disruption results in increased sensitivity to a broad spectrum of
chemicals [44]. To this aim the PDR5 gene was modified by PCR-
mediated integration of the ICORE disruption cassette starting
from the yLFM-PUMA strain. The resulting yLFM-PUMA
pdr5::ICORE strain was then further modified by replacing the
ICORE cassette with a PCR product obtained by amplifying the
Renilla reporter cDNA starting from the yRFM strain and using
PCR primers containing tails of homology for the ICORE
integration flanking sites at the PDR5 locus. Alternatively, the
ICORE cassette was removed from the PDR5 locus using a short
oligonucleotide to simply recycle the cassette and leave a complete
deletion of the targeted gene. Sequences of all primers for targeting
and colony PCR analysis are available upon request.
Small volume dual luciferase assays in yeast
Yeast transformants were selected on plates selective for the
presence of the p53/MDM2/53BP1 expression vectors. Overnight
cultures (1 ml) were grown in glucose liquid medium to keep p53
expression repressed. The cultures were then washed in selective
medium containing 2% raffinose as carbon source and diluted to
OD600nm ,0.1 in media containing 2% raffinose and a desired
amount of galactose (see Results section) for the induction of the
GAL1 promoter that drives p53 expression. 100 ml of cell
suspensions were placed in 96-well plates. When needed the
desired concentration of the small molecules RITA, Nutlin and
PRIMA-1 were added to the cell suspension in the 96-well format.
The 96-well plate was then incubated for 16 hrs at 30uC under
moderate (150 rpm) orbital shaking. Immediately prior to the
luciferase assays, cultures were resuspended and 10 ml were
transferred to a white 384-well plate. OD600 was directly measured
in the 96-well plate. For the luciferase assay, 10 ml of PLB buffer
2X (Passive Lysis Buffer, Promega, Milan, Italy) were added to the
10 ml cell cultures, and the 384-well plate was placed on a
thermomixer and incubated for 15 min at room temperature with
the shaker set at 500 rpm. 10 mlo fFirefly luciferase Bright Glo
substrate (Promega, Milan, Italy) were then added to the cell
suspension and light units were measured in a plate reader
(Mithras LB940 plate reader -Berthold Technologies, Milan, Italy
or Infinite M-200, Tecan, Milan, Italy). For the dual-luciferase
assay, 5 ml of the Firefly luciferase substrate (Luciferase Assay
Reagent, LARII, Promega) followed by 5 ml of the Stop&Glow
buffer were used instead of the Bright Glo, (Promega) to measure
Renilla activity.
Larger volume luciferase assay in yeast
The results obtained with the newly developed small volume
luciferase assay were compared to those obtained with an
intermediate protocol that utilized 1 ml liquid cultures to induce
p53 expression. Luciferase activity was determined without the
laborious extraction of soluble proteins by mechanical lysis and
centrifugation. To this aim, 0.5 ml of the cultures were collected
by centrifugation after the 16-hour growth in the desired p53-
inducing conditions. Cells were suspended in 0.5 ml of 1x PLB (or
CCLR) lysis buffer and incubated for 15 min. at room
temperature. 10 ml of cell suspensions were then transferred to a
white 96-well plate and 50 ml of Bright Glo reagent were added for
the luciferase assay. 100 ml of the cell suspension were also
transferred to a transparent 96-well plate to measure the OD600nm
that was used as normalizing factor. The dual luciferase assay was
developed similarly, except for the use of 10 ml of the Firefly
substrate and 10 ml Stop&GlowH Renilla substrate.
Protein extraction and luciferase assay
The results obtained with the newly developed small volume
luciferase assay were also compared with the previously developed
protocol that relies on 1 to 2 ml liquid cultures of yeast
transformants and soluble protein extraction [31,45]. Briefly,
purified transformants with the desired p53 expression plasmids
were cultured to induce p53 expression for 16 hrs in 2 ml of
synthetic selective medium. Cells were then collected by
centrifugation, washed in sterile water and suspended in 100 ml
of GLO lysis buffer (Promega, Milan Italy) and an equal volume of
pre-chilled glass-beads (,0.5 mm, Sigma-Aldrich) was added.
Protein lysates were obtained from mechanical lysis of the cells
obtained using a vortex mixer. Protein extracts were cleared by
centrifugation (15 min at ,16000 g at 4uC) and quantified using
the BCA Protein Assay (Pierce Biotechnology, Milan, Italy).
Luciferase activity was measured using a multilable Mithras
LB940 plate reader (Berthold technologies, Milan, Italy) or Infinite
M-200 plate reader (Tecan) using 10 ml of extracts and 50 ml of the
Bright-Glo assay reagent (Promega).
Western Blot
Yeast transformants were grown overnight in selective galac-
tose-containing medium and an equivalent amount of cells, based
on the culture absorbance measurement (OD600nm), were collected
the day after in 1.5 ml tubes by centrifugation (1 min 614000 g).
Cells were washed once with 1 ml of sterile water and harvested
again by centrifugation. Pellets were then resuspended in 300 mlo f
lysis buffer (0.025 M Tris-HCl pH 6.8, 0.015 M NaCl, 10%
glycerol, additioned with 0.01 M PMSF and 1x complete protease
inhibitor cocktail (Roche, Milan, Italy). One volume of acid-
washed glass beads (0.4–0.5 mm diameter, Sigma, Milan, Italy)
was added to the cell suspension and lysis was obtained by 6 cycles
of 30 sec. vortex at high setting, each followed by 30 sec. on ice.
Soluble proteins were then obtained after centrifugation at 4uC for
10 min. at maximun speed. Supernants were transferred and
proteins quantified using the BCATM method (Pierce, Thermo
Scientific Milan, Italy). Protein extracts were boiled at 95uC for
5 min., resolved with SDS-Page on 7.5% BisTris Acrylamide gels
using a Biorad MiniProtean III apparatus (Bio-Rad, Milan, Italy)
and transferred to Nitrocellulose or PVDF membranes using the
semidry iBlot system (Life Technologies, Milan, Italy). After
blotting the quality as well as the equal loading and transfer of
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membranes were probed with monoclonal or polyclonal antibod-
ies specific for p53 (pAb1801 and DO-1, Santa Cruz Biotechnol-
ogy) MDM2 (SMP14, Santa Cruz Biotechnology, D.B.A. Italia,
Milan, Italy) and actin (I-19-R, Santa Cruz Biotechnology). The
relative Molecular mass (Mr) of the immunoreactive bands was
determined using molecular weight markers (Fermentas, Milan,
Italy). After washing, blots were incubated with the appropriate
IgG- horseradish peroxidase conjugated secondary antibody
(Santa Cruz Biotechnology), and immune complexes were
visualized with ECL plus reagent (GE Healthcare) using a
Molecular Imager ChemiDoc XRS+ system (Bio-Rad). Band
intensities were quantified using the Image-Lab software (Bio-
Rad).
Results
Development of a small-volume, dual-luciferase assay to
study p53 transactivation potential
In previous studies [30,31,32,33,38], we reported several
modifications to the original yeast-based ADE2 color (red/white)
p53 functional assay [46]. The p53 gene was placed under the
control of the finely-tuned inducible GAL1,10 promoter (‘‘rheos-
tatable’’) to address transcriptional issues that are dependent upon
protein levels. This system revealed subtle differences in p53
function at many target sequences and identified mutants with
enhanced or altered transactivation capacity including change-of-
spectrum mutants [47]. The ADE2 reporter was replaced with the
more quantitative Firefly luciferase and the system incorporated a
convenient in vivo mutagenesis system based on oligonucleotides
[40] that enabled us to easily create isogenic yeast reporter strains
differing only in the p53 RE target sequence driving the luciferase
reporter [38]. The resulting system provided opportunities to
address the transactivation potential of p53REs, functional SNPs
in p53 REs and noncanonical REs [30,31,32,33].
While very informative, the requirement for 1 to 2 ml cultures
per experimental condition and soluble protein extraction to
quantify Firefly luciferase activity limited the experimental
opportunities. Thus, we sought to develop a miniaturized system
that did not require protein extraction. As described in the
following, we found that cells in growth phase as well as stationary
of both the haploid and diploid strains we developed could be
permeabilized for uptake of luciferase substrate if resuspended in
Passive Lysis Buffer (PLB) or Cell Culture Lysis Reagent (CCLR)
from Promega (Milan, Italy) without leading to the appearance of
soluble protein in the solution. There was a time-dependent loss of
viability in PLB buffer (survival was ,10% after 1 hr incubation at
room temperature). Cells were incubated for 10 min in the PLB
prior to the addition of the Firefly luciferase substrate. Since the
permeabilized cells retained structural integrity, the optical
densities (OD600nm) of cell suspensions could be used for
normalization. The assay provides robust measurement of p53-
dependent transactivation, as shown in Figure 1A. The transacti-
vation potential of wild type (WT) p53 and the D368 deletion
mutant lacking the regulatory domain in the p53 carboxy terminus
(C-ter) were determined using three reporter strains and four
galactose concentrations to modulate p53 expression. The results
are in agreement with our previous analysis of the same p53
proteins and REs using luciferase measurements following protein
extraction [31].
We also examined the robustness of the system for detecting
luciferase activity within small culture volumes (100 ml) using 96-
well plates and sampling 10 ml aliquots. In these experiments both
WT and the partially functional R282Q mutant were expressed at
variable levels under the inducible GAL1 promoter (Figure 1B and
C) as well as under the constitutive ADH1 promoter (Supporting
Information S1). Relative transactivation potential was measured
from four p53 REs: the strongly responsive P21-59, the moderate
GADD45 and PUMA and the weaker AIP1 [38]. Again, the
results were comparable to those obtained with the traditional
protein extraction and luciferase protocol (compare Figure 1B with
Figure 1C) supporting the use of luminescent reporters, permea-
bilized cells, and small volumes to assess p53 transcriptional
functions as well as providing a high-throughput format.
Genetic modification of reporter strains to improve drug
accumulation
To make our assay more suitable to test different kind of
molecules, we modified the ABC transporter genes to increase the
accumulation of small molecules. Specifically, we took advantage
of a disruption cassette for the PDR1 (pleiotropic drug resistance)
gene, a regulator of the ABC-transporter system, that replaces the
WT gene with a chimeric construct in which the PDR1 DNA
binding domain is fused to a transcriptional repressor domain.
This chimeric gene provides dominant enhanced sensitivity to a
variety of chemicals [39] in yeast. We also disrupted the p-
glycoprotein gene PDR5, resulting in increased sensitivity to a
broad spectrum of chemicals [44,48,49]. Growth of the ABC
mutants was examined in liquid cultures under the same
conditions used for the luciferase protocol described above (see
Materials and Methods). As shown in Figure 1D, the growth rates
appeared comparable to WT in raffinose and galactose-containing
medium after an initial delay following transfer from glucose
medium (Figure 1D). The same results were observed both in rich
and synthetic, glucose-containing medium (Supporting Informa-
tion S1 and data not shown). For all the galactose concentrations
used in this study (up to 0.064%) we did not detect an impact of
p53 expression on growth parameters of the yeast cultures nor a
distinct impact of the genetic modifications targeting the ABC
transporter system (not shown). To examine the impact of these
genetic modifications on drug accumulation in our strain
background, we evaluated the toxicity of cycloheximide [39]
(Supporting Information S1). Results confirmed that both PDR1
and PDR5 disruption rendered the cells more sensitive to the drug.
The pdr5 mutant was the most sensitive although, surprisingly, the
double mutant pdr1, pdr5 exhibited a slightly reduced sensitivity
compared to pdr5. Although the specific impact of the PDR1 or
PDR5 deletions could be dependent on the nature of the small
molecule tested [48], based on the observed relative sensitivity in
this work we focused on the pdr5 mutant to develop the
modifications of the yeast-based assay.
Dual-luciferase system to study p53-dependent
transactivation
The system was further modified to include a Renilla reniformis
cDNA luminescent reporter that could be used for internal
normalization rather than relying on cell density. We established
that Renilla activity can also be measured in cell suspensions
prepared in PLB or CCLR lysis buffers by comparing p53-
dependent transactivation potential in a pair of strains containing
the Firefly or the Renilla reporters cloned downstream of the
moderate p53 RE derived from the human PUMA target gene
(the OD provided a normalizing parameter), as shown in
Figure 2A. To develop the Renilla reporter as an internal standard,
the Renilla cDNA was placed downstream from the minimal CYC1
promoter, previously used for the Firefly luciferase [38] without the
introduction of a p53 RE. This CYC1-Renilla minimal promoter-
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terminal deletion measured in permeabilized cell cultures and normalized to optical density OD. p53 proteins were induced at different levels by
varying the amount of galactose, as indicated. Three different p53 response elements (REs) that differed in relative transactivation capacity from very
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expression of the control luciferase, was cloned at the PDR5 locus
(pdr5:REN) in the yLFM-PUMA reporter strain. The p53
responsiveness of this dual-luciferase system is depicted in
Figure 2B. Luciferase activities could be detected using only
10 ml of cell suspension and 5 ml of standard luciferase substrate
and were comparable to those obtained using our previous
approaches that involved lysis by glass beads and larger volumes
[31,33].
To directly compare the different approaches for detecting p53
transactivation, the WT p53 and the R282Q mutant were tested
in the following manner: i) 2 ml cultures of cells were lysed with
glass beads; ii) 500 ml of the 2 ml cultures were transferred into
1.5 ml eppendorf tubes and permeabilized with 100 ml of 1x lysis
buffer; and iii) 100 ml cultures were incubated in 96-well plates of
which 10 ml were transferred into 384-well plates and permeabi-
lized by an equal volume of 2x PLB lysis buffer. As shown in
Figure 2C, the miniaturized dual-luciferase assay provides a
sensitive and robust system for addressing p53 dependent
transactivation in a format that is amenable to high-throughput
screens.
Functional interactions between p53 and MDM2 or
53BP1 using the yeast-based dual luciferase assay
A goal in the development of the dual luciferase system was to
obtain a suitable assay to address interactions of p53 with factors
that determine its stability and to identify chemicals that could
modify those interactions. Specifically, we addressed the functional
interaction between p53 and MDM2 and the impact of small
molecules targeting this interaction. MDM2 is a critical inhibitor
of p53 functions that can bind p53 in the amino terminal (N-ter)
region and lead to p53 protein degradation via its E3 ubiquitin-
ligase activity in human cells [50]. For these experiments we
generated diploid reporter strains that could select for the MDM2
expression vector (see Materials and Methods). The diploid cells
were heterozygous for the PDR5 deletion. Consistent with a
previous report [51], we found that in yeast MDM2 co-expression
resulted in a reduction of p53-dependent transactivation. Initially,
we explored the impact of MDM2 on the ability of increasing
amounts of p53 protein to transactivate the ADE2 red/white
reporter from an upstream p53 RE [30,38]. The MDM2 cDNA
was expressed constitutively under the moderate PGK1 promoter.
Reduction of p53-dependent transactivation by MDM2 was
observed only at very low levels of p53 expression (Supporting
Information S1, raffinose only vs raffinose + galactose plates) and
was affected by amino acid changes in the p53 N-ter mimicking
post-translational modifications. The MDM2 inhibition of p53
activity in this semi-quantitative assay was dependent on the p53
RE examined and was observed only with the highest p53 affinity
REs, p21-59 and CON, being suitable for the ADE2 reporter assay.
The impact of MDM2 on p53 WT and mutants was
subsequently evaluated using a luciferase-based assay. Specifically,
serine/threonine residues in the N-terminal domain were mutated
to mimic phosphorylation events in mammalian cells or to prevent
phosphorylation; these residues are modified as part of the
signaling pathways that activate p53 by influencing protein:protein
interactions including that with MDM2 [52,53,54]. As shown in
Figure 3A, we confirmed that MDM2 could inhibit p53-
dependent transactivation from different p53 REs. The impact
of the mutations was in part dependent on the nature of the p53
RE driving Firefly luciferase expression. In particular the T18E and
S20D p53 mutants were less sensitive to MDM2-dependent
inhibition of transcription at a moderate RE (Killer/DR5) than
with a strong RE (p21-59). On the contrary, transactivation at
either RE by p53 mutants mimicking constitutive phosphorylation
(referred to as ‘‘4D’’ and ‘‘6D’’ in the figure) was largely insensitive
to co-expressed MDM2. The transactivation potential of those N-
ter p53 mutants when expressed alone was comparable to WT p53
with the exception of the multiple mutant 6A, where the
concomitant change of Ser 15, 20, 33, 37, 46 as well as of
threonine 18 into alanine resulted in approximately three-fold
higher activity (Supporting Information S1).
The impact of MDM2 co-expression on WT p53 protein levels
was also assessed using western blot analysis (Figure 3B & C). p53
protein levels were determined from cells grown in glucose (steady-
state) or from cells grown in galactose for 16 hrs to induce p53 and
then transferred to glucose media to repress the transcription of
the p53 cDNA to estimate the p53 protein half life in yeast. p53
protein amounts were quantified relative to b-actin loading
control. A 10% reduction in steady-state p53 protein amount
due to the co-expression of MDM2 was observed in the galactose-
induced cultures (Figure 3B lanes 3 & 4). Furthermore, MDM2
appeared to reduce p53 half life in yeast, based on relative
quantitation of the immunoblot at the various time points after the
transfer of the cells to glucose medium. p53 half life was estimated
to be ,2.5 hours in cells that express MDM2 and 5 hours when
MDM2 was not expressed (Figure 3C). MDM2 protein levels also
appeared to vary during the experiment, in relation to the growth
phase of the cultures. A previous study reported that the PGK1
promoter that controls MDM2 cDNA expression in the vector we
used, could be severely repressed in stationary phase cells, while
remaining largely unaffected by changes of carbon sources in the
medium [55]. It is important to note that all the luciferase assays in
our work were conducted in cultures grown for 16 hrs in
galactose-containing medium, when cells are still in a late-
logarithmic culture phase. A previous study in yeast where
MDM2 and p53 were co-expressed under a GAL promoter
reported a similar impact of MDM2 on p53 protein half life [56].
Overall, these results strongly suggest that the functional
interaction between p53 and MDM2 is at least in part dependent
strong (CON, an optimized consensus sequence), to strong (P21, corresponding to the p21-59 site) and to moderate (GADD45). OD of the cultures was
used as normalizing factor. Presented are the average measurements and standard deviations of three biological replicates. (B, C) Small-volume yeast
cultures can determine p53 transactivation capacityRelative transactivation capacity of WT and the R282Q p53 have been compared towards four
different REs obtained with the traditional assay based on 2ml liquid cultures in individual tubes (B) and with the permeabilized assay format based
on 100 ml cultures prepared directly in 96-well plates (C). p53 proteins were induced at different levels by varying the amount of galactose, as
indicated. A strong (P21), two moderate (PUMA, GADD45) and a weak RE (AIP1) were compared. Cells collected from the two different culture
protocols were used for the measurement of luciferase activity as described in the Materials and Methods section. Presented are the average fold-
induction of luciferase by p53 proteins relative to the activity obtained with an empty vector; included is the standard deviations of three replicates.
(D) Impact of genetic modifications of the ABC-transporter systems on yeast growth. Overnight liquid cultures in synthetic medium containing
glucose were washed and resuspended in fresh medium containing raffinose (2%) as the carbon source and low levels of galactose (0.0032%) (time
zero) to induce p53 protein expression. Cultures were diluted to ,0.1 OD600nm, as measured by a plate reader. OD was measured at the 6, 12, 24hr
time intervals. Error bars plot the standard deviations of three biological replicates. The average absorbances are also presented to the right of the
graph.
doi:10.1371/journal.pone.0020643.g001
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mammalian cells but does not lead to a strong reduction in p53
protein stability. Thus, the impact of MDM2 in yeast is likely due
to a competing effect for p53 binding to components of the
transcription machinery, as suggested previously [51].
We extended the study of p53 interactors in the dual-luciferase
system to 53BP1 using a yeast-expression vector containing a
53BP1 clone with N-ter deletion of the first 970 amino acids [51].
53BP1 was identified in a 2-hybrid screen by its ability to bind the
DNA binding domain (DBD) of p53 through the BRCT domains
present in the C terminal region (C-ter) of 53BP1 [57]. While
53BP1 was shown to act as a positive cofactor for p53 function in
human cells [58], its co-expression with p53 (WT or mutant) in our
yeast-based assay led to a reduction in p53-dependent transactiva-
tion (Figure 4 and 5C), consistent with a previous study [51]. This
result indicates that 53BP1 might compete with p53 for sequence-
specific binding to DNA. Unlike the general inhibition by MDM2,
the impact of 53BP1 differed towards specific partial-function p53
missense mutants, consistent with the p53:53BP1 physical
interaction. For example, transactivation by the R181L and
R282Q mutant proteins were slightly or not affected by 53BP1,
while the transactivation by A119V, P219L and R283H was
reduced by co-expression of 53BP1 (Figure 4).
The small molecules Nutlin and RITA can reduce the
inhibitory effects of MDM2 and 53BP1
Using the dual luciferase system we then investigated the
impact of two well-known small molecules than can affect p53,
namely Nutlin and RITA. The former can disrupt the interaction
between p53 and MDM2 by binding to MDM2 while RITA can
interfere on the same interaction by targeting p53, possibly
leading to conformational changes [59]. As summarized in
Supporting Information S1, we did not observe a significant
impact on yeast growth under the conditions used for the WT
strain or for the ABC-transporter mutants, although the mutants
experienced a delay in growth following the shift in media (also
described in Figure 1). While Nutlin had little impact on
transactivation by p53 alone it counteracted the negative impact
of MDM2 (Figure 5A).
Treatment with RITA led to a severe reduction in p53-
dependent Firefly luciferase activity (Figure 5B). However, also the
basal luciferase activity was affected by RITA, indicating that the
effect might not be related to p53. A negative impact of RITA on
Firefly luciferase activity was previously reported in mammalian
cells [60]. However, RITA had no impact on the basal activity of
the Renilla luciferase. We, therefore, constructed a dual luciferase
reporter strain in which the Renilla luciferase was placed under p53
transcriptional control. In this strain, treatment with RITA had no
effect on p53-induced transactivation detected by the Renilla
luciferase (Supporting Information S1). After taking into account
the impact of RITA on basal Firefly luciferase activity, we were
able to show that RITA could partially relieve the inhibition of
p53-dependent transactivation by MDM2 (Figure 5C). The
impact of Nutlin and RITA on the p53/53BP1 functional
interaction was also examined. Treatment with Nutlin did not
modify the 53BP1-dependent inhibition of p53-dependent trans-
activation (Figure 5C). However, the inhibition was partially
relieved by RITA. Western blot analysis confirmed that MDM2
co-expression had little impact on p53 protein levels after culturing
cells for 16 hrs in 0.012% galactose. Interestingly, treatment with
Nutlin but not RITA appeared to reduce MDM2 expression/
stability (Figure 5D).
PRIMA-1 exhibited an apparent lack of impact on p53
mutants
The dual luciferase system was investigated for its responsive-
ness to PRIMA-1, a small molecule identified in a mammalian
cell-based screen for chemicals that could induce apoptosis in a
mutant p53-dependent manner [35]. PRIMA-1 restored se-
quence-specific DNA-binding and transcriptional transactivation
to mutant p53 in vitro, possibly through altering mutant p53
conformation or folding stability [61] although the precise
mechanism remains to be determined. To examine the impact
of PRIMA-1, we chose a panel of p53 mutations that differ in
their relative transactivation capacity in the yeast-based assay.
Four loss-of-function mutants were tested, including the two
cancer hotspot mutants R175H and R273H that were shown to
be responsive to PRIMA in human cells [35]. We also examined
5 partial function p53 mutations since they could register negative
and positive impacts of small molecules. The transactivation
potential of the p53 mutants ranged from 50 to 80% of the WT
protein in the reporter strain containing the PUMA p53 RE
under moderate expression from the GAL1 promoter. As
described in the supplementary material, we were unable to
detect any effect of PRIMA-1 on transcription by WT or mutant
p53 in WT (not shown) or in pdr5 mutant cells (Supporting
Information S1).
Discussion
In this study we have greatly expanded the features of our
previously described yeast strains for assessing p53 and p53 RE
function in order to develop a system that is both more efficient
and miniaturized. The system provides for rapid assessment of p53
transactivation potential as well as the impact of p53 mutations,
cofactors and small molecules. In particular, it integrates variable
expression of p53 proteins under the finely tunable GAL1
promoter, single copy luminescence reporters that are chromo-
somally located with opportunities to co-express p53 alleles along
with chosen cofactor proteins coded from selectable low copy
number plasmids. Furthermore, the assay is based on a small-
volume format for p53 expression, treatment with chemicals, and
quantification of the reporter expression and is compatible with
high-throughput screening.
Figure 2. Either Firefly or Renilla luciferase can function as p53-dependent reporters. (A) The ability of Firefly and Renilla cDNAs to serve as
reporters for p53 transactivation was examined by placing them downstream from the moderate p53 RE derived from the PUMA promoter in
isogenic strains. The values indicate the fold induction measured over an empty vector. Presented are average and standard deviations of three
replicates relative to optical density of the cultures measured at different times (T in hrs) after switching cultures to galactose-containing medium. (B)
Dual luciferase reporter assay with a strain expressing WT p53 and containing the Firefly luciferase as p53 reporter gene and the Renilla luciferase as
constitutive reporter. Presented are the average and standard error of the Firefly luciferase activities normalized for Renilla and compared to empty
vector at various time points after shifting 100 ml yeast cultures to galactose-containing media in the 96-well plate format. (C) Comparison of relative
induction using measurement of protein from 2 ml cultures vs direct permeabilization of cells in a 384 well format following transfer from a 96-well
growth plate, as described in the text and the Materials and Methods section. Relative transactivation capacities of WT p53 and the R282Q mutant in
the ‘‘2 ml vial’’experimental set-ups were measured using either protein extraction or permeabilization. Experiments were conducted using 0.032%
galactose inducer, unless specified otherwise. Error bars plot the standard error of four biological replicates.
doi:10.1371/journal.pone.0020643.g002
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stability. (A) The functional interaction between p53 and MDM2 was examined using two different reporter strains, as indicated. Transformants were
cultured in 0.012% galactose to achieve low expression of p53 for 16 hours. MDM2 is expressed under the constitutive PGK1 promoter. Besides WT
p53, several mutants at Ser/Thr in the p53 N-ter were tested. The activity of each p53 mutant was set to one to better focus on the relative impact of
MDM2 co-expression on p53 transactivation capacity. The relative transactivation potential of the various p53 mutants is presented in Supporting
Information S1; 4D refers to a quadrupole mutant with S15D, T18E, S20D, S33D changes in p53 . 6A indicates a multiple mutant with alanine changes
at S15, T18, S20, S33, S37, S46. 6D indicates a multiple mutant with aspartic acid changes at S15, S20, S33, S37, S46 and a glutamic acid change at T18.
Presented are the average fold-inductions by p53 proteins compared to empty vector and normalized using the Renilla control luciferase. These
assays were conducted with diploid strains that were obtained by crossing the indicated yLFM- p53 reporter strains with the BY4704 strain (see
Materials and Method section) using the permeabilized format. (B) Western blot analyses of p53 and MDM2 protein levels. O/N cultures in synthetic
glucose medium (GLU) were washed and shifted to medium containing raffinose and 0.012% galactose (GAL) to achieve low expression of p53. The
p53 was expressed under the inducible GAL1 promoter while MDM2 was expressed at constitutive levels from a moderate PGK1 promoter. After
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Specifically, we have established that the new, dual-luciferase
based protocol can assess p53-dependent transactivation and the
impact of single amino acid changes in the p53 DBD. We found
that co-expression of MDM2 can lead to reduced p53 transactiva-
tion at low levels of p53 protein expression. p53 mutants at the
DBD that have partial transactivation function were also inhibited
by MDM2, whereas mutations introduced into the p53 N-ter
domain that mimic phosphorylation events could relieve p53 from
the MDM2-dependent inhibition. Those same amino acid changes
did not alter significantly the transactivation potential of the p53
protein, when expressed alone. This suggests that the assay can be
used to reveal ectopic p53:MDM2 physical interactions that are
likely to occur at the p53 N-ter region, similar to the endogenous
interaction in higher eukaryote cells. The assay also revealed a
modest impact of MDM2 on p53 protein stability in yeast.
Although MDM2 was recently found to bind p53 at the DNA
binding domain (DBD) and at the C-ter [62], the primary site of
interaction occurs at the transactivation domain (TAD) in the p53
N-ter region [63].
We also examined the impact on p53 transaction of another
important p53 cofactor, the protein 53BP1. The BRCT domains
present in the 53BP1 C-ter are required for the interaction with
p53 as well as with other important proteins such as BRCA1 [57].
The physical and functional interactions between p53 and 53BP1
in the context of DNA damage response appears to be complex.
Following DNA damage, 53BP1 can localize to nuclear foci in
mammalian cells, is rapidly phosphorylated in an ATM-dependent
manner [64], and is essential for DNA double strand break repair
[65]. Furthermore, 53BP1 appears to be an important mediator of
the induction of senescence and cell death pathways elicited by
BRCA1 deficiency in mice [66]. A crystal structure of p53 DBD
bound to the human 53BP1 BRCT domains led to the
identification of amino acids in the p53 DBD involved in such
interaction [67]. More recently, the Tudor domain of 53BP1 was
shown to interact with p53 proteins dimethylated in the p53 C-ter
region at lysine 382 [68]. The generation of p53 dimethylated at
Lys382 promotes the accumulation of p53 protein that occurs
upon DNA damage but this accumulation is dependent on 53BP1
[69]. These results suggest that the positive coactivator function of
53BP1 towards p53 in mammalian cells [58] may be related to its
positive impact on p53 protein amount. Possibly, 53BP1 reduces
the interaction between p53 and MDM2 (G. Selivanova,
unpublished results).
The co-expression of 53BP1 with p53 leads to a reduction in
p53-dependent transactivation, similar to previously reported
findings in yeast [51]. Unlike MDM2, the impact of 53BP1 was
lost or greatly reduced with specific partial function p53 mutants in
the DBD. For example the p53 R181L mutant was not sensitive to
53BP1. Structural studies showed that p53 R181 formed both a
16 hrs of growth in galactose-containing medium, cells were washed and transferred to glucose medium to repress the GAL1 promoter. Samples
were collected at the indicated time points to prepare protein extracts for western blot. 100 mg (MDM2 and actin, top panel) and 20 mg (p53 and
actin, lower panel) of extract was loaded in each lane. The DO-1, SMP14 and I-19-R antibodies (Santa Cruz) were used for the immunodetection of
p53, MDM2 and actin, respectively.Actin levels were used as a normalization factor to estimate relative MDM2 and p53 amounts. Consistent with a
previous study [55], we observed that MDM2 expression under the PGK1 promoter was affected by the culture state and was particularly reduced
when cell approached the stationary phase (O/N in glucose; T8 and T12 time points; at T12 cells were diluted for the additional 12 hr time point). The
relative changes in MDM2 and p53 protein amounts compared to the level observed in glucose cultures are indicated above the immunoblot. (C)
Quantification of p53 expression relative to the amount observed after 16 hrs in 0.012% galactose, normalized to actin levels. A 10% reduction in
steady-state p53 protein amount due to the co-expression of MDM2 was observed in the galactose-induced cultures. To better visualize the impact of
MDM2 on the estimated p53 half life (EHL) the relative amount of p53 observed after 16 hrs in galactose was set to 100%, both for extracts of cells
expressing only p53 or p53 + MDM2.
doi:10.1371/journal.pone.0020643.g003
Figure 4. Functional interactions between partial function p53 mutants and MDM2 or 53BP1. Mutant p53 expression was under the
control of the GAL1 promoter while MDM2 or 53BP1 (a clone containing a N-ter deletion of the first 970 amino acids) were expressed at constitutive
levels under the PGK1 and ADH1 promoters, respectively. p53 expression was induced for 16 hrs in medium containing 0.012% galactose. Presented
are results describing the impact of MDM2 or 53BP1 on transactivation of various p53 mutants that are capable of partial transactivation toward the
PUMA RE. To better visualize the impact of MDM2 and 53BP1, the activity of each p53 mutant alone is set to 100%. The relative light units of the







Significant differences in activity relative to p53 alone are shown (*: p,0.01; ‘:p ,0.05, Student’s t-test).
doi:10.1371/journal.pone.0020643.g004
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the BRCT domains [67]. The reduced interaction between the
p53 mutant R282Q and 53BP1 could not be linked to the reported
physical interaction between the two proteins.
Overall, our results indicate that the dual-luciferase yeast-based
assay can be used to study the interaction between p53 and
cofactor proteins. While the functional interaction appears
dependent on conserved physical interactions, the outcomes of
the co-expression on p53-dependent transactivation in the yeast
assay does not always reflect expectations from mammalian cells,
although such discrepancies can be reasonably explained and
related to the defined nature of the assay, as proposed above for
the impact of 53BP1.
Impact of small molecules
Having established that the yeast-based assay can reveal a
functional interaction between p53 and its cofactors MDM2 or
53BP1, we explored the impact of small molecules targeting those
interactions using Nutlin and RITA. Nutlin had been isolated as a
small molecule that interacts with the p53-binding pocket in
MDM2, resulting in accumulation of p53 protein and possibly
inhibition of MDM2 activity towards other of its targets
[10,59,70]. Treatment with Nutlin led to p53 accumulation in a
variety of cancer cell lines, without significant induction of p53
post-translational modifications, and resulted mainly in cell cycle
arrest, although apoptosis was also detected. The compound
showed p53-dependent growth suppression in in vivo experiments
without much evidence for toxicity in nude mice. The small
molecule RITA (reactivation of p53 and induction of tumor cell
apoptosis) was obtained in a cell-based assay screening for
induction of WT p53-dependent apoptosis [25]. Its mechanism
of action appears to be at least in part related to a direct
interaction with the p53 protein and inhibition of the p53-MDM2
binding. Differently from Nutlin, which directly affects the binding
of MDM2 to the amino-terminal region of p53, RITA was
reported to bind the p53 N-ter region and indirectly affect the
Figure 5. Functional interactions between wild type p53 and
MDM2 or 53BP1 and the impact of Nutlin and RITA. WT p53 was
expressed at low-level achieved by culturing cells in medium containing
0.012% galactose for 16 hrs in the 96-well plate format. MDM2 was
expressed from the moderate PGK1 promoter. (A) The impact of MDM2
on p53-dependent transactivation was examined in the presence of
different concentrations of Nutlin added to the medium at the time of
the switch to galactose-containing medium using a reporter strain
containing the moderate PUMA p53 RE. The average transactivation
relative to the basal level of reporter activity measured in cells that do
not express p53 and standard deviations of three biological repeats are
presented. Significant differences in activity relative to p53 alone are
shown (*: p,0.01, Student’s t-test). (B) Firefly luciferase activities
normalized using the control luciferase Renilla are presented for empty
vector and wild type p53 in the presence of different amounts of RITA.
(C) Nutlin and RITA impact on the functional interactions between p53
and MDM2 or 53BP1. Nutlin (20 mM) or RITA (0.5 mM) were added at the
time of switching cultures to galactose-containing medium. The
luciferase activity by wild type p53 alone, normalized using the Renilla
control luciferase, is set at 100%. Both MDM2 and 53BP1 co-expression
reduced p53-dependent transactivation. Nutlin partially relieved the
functional impact of MDM2, but not that of 53BP1. RITA partially
relieved p53 from the inhibition by both MDM2 and 53BP1. Significant
differences are shown (*: p,0.01; ‘:p ,0.05, Student’s t-test). (D) MDM2
and p53 immunoblot in mock-, RITA- and Nutlin-treated yeast cells.
Proteins were prepared from cells grown in medium containing 0.012%
galactose for 16 hrs and treated with DMSO solvent control 0.5 mM RITA
or 20 mM Nutlin. 25 mg were loaded to detect p53 and 100 mgo f
protein extracts were loaded to probe for MDM2. Actin was used as a
loading control.
doi:10.1371/journal.pone.0020643.g005
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p53-dependent apoptosis in a variety of tumor cell lines [25].
Our results establish that treatment of yeast cells with the small
molecules Nutlin or RITA could partially relieve WT p53 from
the MDM2-dependent inhibition, similar to what is observed in
mammalian cells. Furthermore, while Nutlin treatment had no
impact on the functional interaction between p53 and 53BP1,
RITA was also able to target the p53/53BP1. Combined with the
observation that 53BP1 appeared to interact with p53 mutants in a
manner that is mutant-specific, our results suggest that the yeast-
based assay could be used to screen a large panel of tumor-
associated p53 mutations for differential impact of these chemicals
on p53 functional interaction with cofactors.
Attempts to modify WT or mutant p53 function by PRIMA-1
were unsuccessful. PRIMA-1 was reported to restore the sequence-
specific DNA-binding and transcriptional transactivation of some
p53 mutants in vitro and to suppress tumor-cell growth in mice by
inducing apoptosis (Bykov et al., Nat Med. 2002). Interestingly,
PRIMA-1 inhibited the growth of cell lines derived from various
human tumor types in a mutant p53-dependent manner [71]. The
precise mechanism of action of this compound is not clear;
moreover its selectivity for mutant p53 remains to be fully
established and may also be related to indirect effects on p53
folding and nuclear localization. For example PRIMA-1 induced
the expression of heat shock protein 90 (Hsp90) in breast cancer
cells, restored the p53-Hsp90 interaction and enhanced the
translocation of the p53-Hsp90 complex to the nucleus [72].
Recently the ability of PRIMA-1 to induce nucleolar localization
and degradation of mutant p53 protein has been demonstrated
[73], suggesting the existence of a complex mode of action, likely
cell-type specific, that can be independent from the restoration of
transactivation functions to mutant p53. Indeed, PRIMA-1 fails to
stimulate the DNA binding potential of isolated mutant p53 DBD
in vitro [59]. The apparent lack of effect of PRIMA-1 in our assay
might be due to poor uptake, even in the pdr5 mutant, or
modification of the chemical in yeast. It has been shown that
PRIMA-1 is converted to compounds that forms adducts with
thiols on mutant p53 and such p53 protein modifications can
trigger apoptosis [61]. It might well be that these activating
modifications are impaired in yeast.
Overview
Cell-based functional assays are expected to be useful tools for
identifying molecules targeting mutant p53 or impacting on the
interaction between p53 and cofactors. They can provide unbiased
screening opportunities for leads that act beyond steric hindrance
of protein:protein interactions including allosteric modifiers of
protein folding or stability. Allosteric modulators could be
combined potentially with rationally designed drugs to increase
potency or overcome single agent resistance in vivo [74]. In this
regard initial studies suggest that the combination of Nutlin and
RITA might provide additional stimulation of p53-induced
responses, consistent with the different broad transcriptional
responses induced by the two compounds when given as single
agents [75]. However, off-target effects that impact the biological
endpoints being measured, such as the induction of apoptosis, can
hamper identification of mechanisms of action of molecules
scoring positively in cell-based screening assays. This potentially
limiting feature is especially relevant in the case of proteins like
p53, whose functions are wired into many cell-signaling pathways.
Furthermore, the tremendous variability in tumor-associated p53
mutations and in expression levels of distinct p53-interacting
proteins and p53 splice and promoter variants as well as p53-
related proteins p63 and p73 could significantly affect the outcome
of small molecule treatments. The yeast-based assay described
here has the advantage of generally being free of p53 biological
consequences. Alternatively, assays have been developed that
exploit the impact of moderate/high levels of p53 expression on
the growth of yeast [76,77]. This type of assay provides the
opportunity to score the effect of cofactors or small molecules that
may also act on p53 transcriptional-independent functions.
However, the exact mechanisms of p53-mediated growth
retardation in yeast are not well-defined. The growth retardation
could be, in part, dependent on effects on transcriptional
complexes, based on our previous identification of toxic p53
alleles in yeast that at low expression levels result in enhanced
transactivation capacity and on the loss of the toxicity caused by
second-site loss-of-function missense mutations in p53 ([47,78].
The spectrum of missense p53 mutations associated with
sporadic and familial cancer comprises more than 1200 distinct
sporadic and ,110 germline mutations (www.iarc.fr/P53/) [79].
Furthermore, biochemical, and functional assays have revealed
that the degree of thermodynamic as well as folding instability
caused by the mutations and their impact on sequence-specific
transactivation function can vary greatly [30,80,81]. These
differences could impact the activity of small molecule modifiers.
Furthermore, the efficacy of allosteric modifiers could be
significantly affected by the cellular/nuclear amounts of p53
mutant proteins or by the ratio between wild type p53 and specific
negative cofactors, such as MDM2 or MDM4. Finally, the impact
of small molecules could be, in part, influenced by the nature of
the interaction between p53 and its many different cognate
response elements located in the large number (hundreds) of
human p53 target genes [82,83,84].
In summary, we propose that the miniaturized yeast dual
luciferase system we developed provides a genetically well-defined,
robust and cost-effective assay that can be used in parallel to
mammalian cell-based assays to screen molecules or further
evaluate leads that target p53 functions. A specific advantage of
the assay is the potential for high-throughput assessment of a
matrix of factors that include low and variable levels of p53
proteins, nature of the p53 response elements and specific, disease-
associated p53 mutations. All these variables could impact the
activity of small-molecule modifiers of p53 functions. Our assay
system could be particularly relevant for further characterization
of small molecules that may act as allosteric modifiers of p53
functions or p53-cofactor interactions.
Supporting Information
Supporting Information S1 1. Small-volume yeast func-
tional assay with constitutive expression of p53 pro-
teins. Presented is the comparison of the relative transactivation
capacity of wild type (WT) and the R282Q p53 towards four
different response elements (REs) obtained with the traditional
assay based on 2 ml liquid cultures in individual tubes (A,
traditional assay) and with the permeabilized assay format based
on 100 ml cultures prepared directly in 96-well plates (C,
miniaturized assay). p53 proteins were expressed under the
moderate, constitutive ADH1 promoter. Cells collected from the
two different culture protocols were used for the measurement of
luciferase activity as described in the Materials and Methods
section. Presented are the average fold-induction of luciferase by
p53 proteins relative to the activity obtained with an empty
vector; included is the standard deviations of three replicates. In
these experiments the light units per OD for WT p53 and the
p21-59 RE were 2.8610
6 for the 2 ml cultures and 2.5610
7 for
the 100 ml cultures. 2. Impact of genetic modifications at
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cycloheximide. Based on the experiments described by
Stepanov et. al. [39] we used cycloheximide treatment to evaluate
whether the disruption of PDR1 and replacement with the PDR1-
repressor construct, the disruption of PDR5, or the combined
modifications would result in enhanced toxicity in our reporter
strain background. Cells from the indicated strains were
resuspended in sterile water and transferred to a 96-well plate.
Serial dilutions (1:5) were prepared and cells were transferred to
plates containing synthetic medium (SD) with different concen-
trations of cycloheximide using a 48-pin replicator. A rich
(YPDA) and an SD control plates were also spotted for
comparison. Plates were incubated for two days at 30uC. 3.
Phenotypic analysis of the impact of MDM2 on WT and
mutant p53 transactivation. The ADE2-based red/white
assay was used to examine p53 dependent transactivation and the
impact of MDM2. p53 was expressed at low levels under the
GAL1 promoter in media containing only raffinose (2%), or
raffinose plus 0.002%, 0.004% or 0.016%, galactose. MDM2 was
expressed from the constitutive PGK1 promoter. p53 transactiva-
tion was examined from three REs upstream of ADE2-based p53
reporter strains as indicated. The optimized consensus (CON)
and P21-59 p53 RE yield levels of high transactivation while the
NOXA RE is weaker [38]. In the ADE2-based p53 functional
assays, cells grown on plates containing a low-amount of adenine
(5 mg/L) result in small red colonies when p53 is not present or
not transcriptionally active. p53-dependent expression of ADE2
results in the appearance of colonies with a color ranging from
light red to white, depending on the level of transactivation. To
reveal the dependency of the phenotype on p53 expression levels,
streaks are prepared on glucose plates containing high amount of
adenine (200 mg/L) and the plates are incubated for two days at
30uC, resulting in the appearance of white colonies. These plates
are then replica-plated to a stack of plates containing 2%
raffinose plus various levels galactose along with the low-level of
adenine. The replica plates are then incubated at 30uC for 2-3
days. Images of a section of the replicas are presented. For each
image the upper section corresponds to colonies expressing p53
alone, while in the lower section the colonies also express MDM2.
Various multiple mutants were tested, as indicated. 4. Relative
transactivation capacity of p53 phosphorylation-site
mutants. The activity of the p53 mutants described in
Figure 4 is presented as relative light units in two p53 reporter
strains using the Killer/DR5 or the p21-59 REs upstream of a
luciferase reporter. Results were obtained with the traditional
assay format and are normalized to amount of soluble proteins.
4D refers to a quadruple mutant with the S15D, T18E, S20D,
S33D changes in p53. 6A indicates a multiple mutant with
alanine changes at S15, T18, S20, S33, S37, S46. 6D indicates a
multiple mutant with aspartic acid changes at S15, S20, S33, S37,
S46 and a glutamic acid change at T18. 5. Impact of small
molecules Nutlin and RITA on the growth of WT yeast
reporter strains or the isogenic derivatives with
modified chemical uptake. Overnight cultures grown in
synthetic glucose medium were washed and diluted to ,0.1
OD600nm as measured by a plate reader. (A) The WT strain was
treated with 40 mMo r8 0mM Nutlin (indicated as nutlin 1 and
nutlin 2 respectively) and 1 mMo r2mM RITA (indicated as rita1
and rita2). (B) The indicated mutant ABC-transporter strains
were treated with1 mM RITA (or DMSO solvent control). OD
was measured at the following times: 2, 4, 8, 12 and 24 hrs. Error
bars correspond to the standard deviations of three biological
replicates. 6. Negative impact of RITA on the Firefly
luciferase but not the Renilla luciferase. To confirm that
the negative impact of RITA on the Firefly reporter was not
dependent on modulation of p53 transactivation, an isogenic
derivative strain was developed containing the PUMA p53 RE
upstream of the Renilla luciferase. Wild-type p53-dependent
transactivation was examined in cultures treated with DMSO
control solvent or with 1 mM RITA. Presented are relative light
units normalized to OD600nm of the cultures. The error bars
correspond to standard deviations for three biological repeats. 7.
Apparent lack of PRIMA-1 effects on yeast growth or
p53-dependent transactivation. (A) The small molecule
PRIMA-1 does not affect yeast growth. Overnight cultures grown in
synthetic glucose medium were washed, diluted to ,0.1
OD600nm, as measured by a plate reader, and treated with
200 mM PRIMA-1. Growth curves were compared for the wild
type strain or the indicated ABC-transporter mutants. OD600nm-
was measured at the 2-, 4-, 8-, 12- and 24-hr time points.
Presented are standard deviations for three biological repeats. (B)
The small molecule PRIMA-1 does not impact wild type p53 transactivation
capacity. Cells were grown in glucose-containing media to keep
p53 expression repressed and transferred to galactose-containing
media followed by the addition of PRIMA-1. Dual luciferase
assays were conducted 16 hrs after the treatment. Renilla
luciferase was used as normalization factor. There was no
significant effect of PRIMA-1 on WT p53 transactivation. The
same result was obtained with a diploid yeast strain, in which
both the p53-dependent reporter (Firefly) and the control
luciferase (Renilla) were placed at the ADE2 chromosomal locus
(i.e., heteroalleles), thus removing potential chromatin effects on
reporter expression. The diploid strain was obtained starting from
two isogenic isolates of our yLFM strain background that differ
for the mating type locus. Presented is the fold-induction of the
Firefly reporter over the Renilla reporter relative to strains that do
not express p53, as they contain an empty expression vector. (C)
The small molecule PRIMA-1 does not affect mutant p53 transactivation
capacity. Different p53 alleles were expressed at moderate levels
using medium containing 0.128% galactose. PRIMA-1 (200 mM)
was added to the cultures at the time of the switch to galactose-
containing medium. Presented are the average fold-induction by
p53 proteins compared to empty vector and normalized using the
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